ENTITY

SIGA Technologies (SIGA US)

18
Analysis
Health CareUnited States
SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.
more
Refresh
11 Nov 2023 13:10Issuer-paid

SIGA Technologies - International momentum building towards year-end

SIGA recapped several key developments in its Q3 update, signalling strong top-line momentum going into Q423. Most notably, the recent $18m...

Share
25 Oct 2023 19:10Issuer-paid

SIGA Technologies - EU gateway to tap into new international orders

SIGA Technologies has announced the formation by the European Commission of a joint procurement mechanism to source oral TPOXX initially involves...

Share
09 Sep 2023 13:10Issuer-paid

SIGA Technologies - Notable CMO appointment to position for growth

SIGA Technologies has announced the appointment of Dr Jay K Varma as executive vice president and chief medical officer, while he remains a...

Share
12 Aug 2023 07:10Issuer-paid

SIGA Technologies - Second quarter as expected, onward to H223

SIGA has reported Q223 results, which came in largely as expected, and management has provided key operational highlights. Activity in the second...

Share
29 Jul 2023 00:12Issuer-paid

SIGA Technologies - US exercised (stockpile) options are key catalysts

SIGA Technologies announced that the US Department of Health and Human Services has exercised its procurement options for oral and intravenous (IV)...

Share
x